Sign in

    Karim Sunghani

    Managing Director and Senior Equity Research Analyst at Baird

    Karim Sunghani is a Managing Director and Senior Equity Research Analyst at Baird, specializing in Healthcare Services and Technology research with a particular focus on managed care and healthcare technology firms. He covers companies including UnitedHealth Group, CVS Health, Cigna, Elevance Health, and Centene, and has been recognized for his insightful analysis and strong performance track record, with a success rate above 63% and double-digit average returns per TipRanks metrics. Sunghani began his career in healthcare investment banking at JPMorgan in 2006, later moving to Guggenheim Partners as a Vice President before joining Baird in 2018, where he has steadily advanced to his current leadership role. He is FINRA-registered with Series 7, 63, 86, and 87 licenses and has been acknowledged within the industry for his analytical rigor and well-regarded stock recommendations.

    Karim Sunghani's questions to ACUREN (TIC) leadership

    Karim Sunghani's questions to ACUREN (TIC) leadership • Q2 2025

    Question

    Karim Sunghani, on behalf of Josh Chan from Baird, asked for more color on the statement that the $20 million cost synergy estimate from the NV5 acquisition is conservative and inquired about where additional synergies might be found beyond corporate functions.

    Answer

    CFO Kristen Schultes stated that the team is increasingly excited about both revenue and cost opportunities as they learn more, promising a refined, bottoms-up number in November. Executive Chairman Robbie Franklin added that their optimization approach extends from the corporate level down to the local branch level, aiming to cross-sell services across all regions.

    Ask Fintool Equity Research AI